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Open access uAbstract: The U.S. has been reported as the only country experiencing a decline in incidence rates of
colorectal cancer (CRC), despite increasing prevalence of CRC major risk factors, including the
Western dietary pattern and obesity. This paper presents a hypothesis that improved folate status in
the U.S. is the factor that couldmost likely explain the seemingly contradictory phenomenon, although
a momentary increase in CRC incidence rates was observed in the later 1990s with the initiation of
nationwide folic acid fortiﬁcation.
To corroborate this hypothesis, time trends in CRC incidence rates and death rates in the U.S. were
plotted by age, race, and gender based on data from the Surveillance, Epidemiology, and End Results
(SEER); data were analyzed by simultaneously addressing the following four critical factors: (1) a long
induction period between improved folate status and potential protection of CRC; (2) a change in the
U.S. Food and Drug Administration regulation in 1973 on the dose of folic acid allowed in
supplements; (3) differential impacts of 1973 regulatory change and 1990s mandatory fortiﬁcation by
race; and (4) changes in CRC screening over time in the U.S.
Although this type of analysis precludes a deﬁnitive conclusion, available evidence suggests that the
increase in CRC incidence rates in the later 1990s is unlikely due to folic acid fortiﬁcation and,
assuming a time lag of a decade or longer to see a beneﬁt on CRC, folate appears to be one of the most
promising factors that could explain the downward trend of CRC incidence rates in the U.S.
(Am J Prev Med 2014;46(3S1):S65–S72) & 2014 American Journal of Preventive Medicine Open access under CC BY-NC-ND licIntroductionColorectal cancer (CRC), as the third most com-monly diagnosed cancer and the fourth-leadingcause of cancer death worldwide,1 affects pre-
dominantly developed countries with the Western life-
style.2 Although incidence rates of CRC have generally
increased in developing countries and have stabilized in
developed countries in recent decades, notably, the U.S. is
the only country experiencing a decline in CRC incidence
rates.3 This decline, if not all due to screening, indicates
the presence of increasing prevalence of protective
factors speciﬁc to the U.S. One study that compared
CRC incidence rates observed with those predicted by
MISCAN-COLON model, a simulation model that
estimated secular trends of CRC if changes in the
prevalence of risk factors or screening practice had notartment of Nutrition and Epidemiology (Keum, Giovan-
d School of Public Health; and the Channing Division of
cine (Giovannucci), Department of Medicine, Brigham and
pital, Boston, Massachusetts
rrespondence to: Edward L. Giovannucci, MD, ScD, Depart-
ion and Epidemiology, Harvard School of Public Health, 665
venue, Boston MA 02115. E-mail: egiovann@hsph.harvard.
$36.00
i.org/10.1016/j.amepre.2013.10.025
rican Journal of Preventive Medicine  Published by Else
nder CC BY-NC-ND license.occurred, showed that about half the decline was
accounted for by changes in risk factors and the rest by
screening.4 One potential factor is folate (vitamin B9
found naturally in foods), which is suggested to protect
against CRC by preventing aberrations in DNA synthesis
(DNA uracil misincorporation) and irregularities in
DNA methylation (DNA hypomethylation) that pro-
mote colorectal carcinogenesis.5 Folate status has
increased substantially in the U.S. resulting from a
change in U.S. Food and Drug Administration (FDA)’s
regulation in 1973 on the dose of folic acid (the synthetic
form of folate) allowed in supplements6 and from the
fortiﬁcation (140 μg folic acid/100 g) of ﬂour and grains
with folic acid in the 1990s.7 Of note, although the
fortiﬁcation became mandatory in 1998, it virtually
started from 1996 because of voluntary fortiﬁcation by
food industries immediately after the release of the new
regulation in 1996.7
Past analyses that overlaid the secular trend of CRC
with changes in national folate intake over time created a
concern that excessive folate intake might promote CRC
rather than preventing it.7,8 However, these analyses7,8
are limited by their failure to simultaneously address the
following four critical factors: (1) a long induction period
between improved folate status and potential protection
of CRC; (2) a change in FDA’s regulation in 1973 on thevier Inc. Am J Prev Med 2014;46(3S1):S65–S72 S65
Keum and Giovannucci / Am J Prev Med 2014;46(3S1):S65–S72S66dose of folic acid allowed in supplements; (3) differential
impacts of 1973 regulatory change and 1990s mandatory
fortiﬁcation by race; and (4) changes in CRC screening
over time in the U.S. Thus, this article will examine the
CRC trend in the U.S. in relation to folate intake by
simultaneously accounting for the aforementioned four
factors and consider the potential beneﬁts as well as risks
of increased folate status on CRC.Long Induction Period
A long induction period deserves special attention in the
study of CRC because the progression from normal cells
of the colon and rectum, to small adenomas, to large
adenomas, and ﬁnally to adenocarcinomas, occurs over a
long duration, up to 30–40 years.5 The presence of a long
induction period between adequate folate status and
reduced risk of CRC is evident from both molecular
mechanistic9 and epidemiologic studies.10,11 In a study
that measured total folate concentration in colonocytes
of adenoma patients (cases) and individuals without
adenomas (controls), there was a signiﬁcant decrease in
colonocyte folate levels from the normal tissue of
controls, to the normal tissue of cases adjacent to
adenomas, and to the adenoma itself.9 The lower folate
levels corresponded to increases in uracil misincorpora-
tion and DNA hypomethylation even in normal-appear-
ing, non-neoplastic tissue of cases.9 As it takes at least 10
years in general to progress from non-neoplastic tissue to
cancer diagnosis,12 the presence of such genetic alter-
ations in non-neoplastic cells in the proximal ﬁeld of
adenomas implies that macroscopically undetectable
abnormalities involving folate deﬁciency occur at least
a decade before CRC is apparent. Epidemiologic evidence
also supports a substantial time lag of at least 12–16 years
between folate intake and CRC risk.10,11 Such data
suggest that a protective effect of increasing folate intake
would be reﬂected in incidence rates of CRC only after
allowing for the estimated minimum induction period of
12–16 years.Change in FDA Regulation on Dose of Folic Acid
Although focus has been typically on mandatory folic
acid fortiﬁcation in the 1990s, a marked increase in folic
acid intake dates back to 1973 when the FDA increased
the daily maximum dose of folic acid allowed in supple-
ments and foods from 100 to 400 μg6 (a recommended
dose for women of childbearing age to prevent birth
defects).13 Although its impact was not widespread,
approximately one quarter of the U.S population using
vitamin supplements in 1973 experienced a signiﬁcant
increase in folic acid intake10 along with an additional
rise from fortiﬁed breakfast cereals. Yet, no previousstudy to our knowledge has considered how the increase
in folic acid consumption in 1973 relates to population
incidence and death rates of CRC. More complete
pictures would be obtained if the secular trend of CRC
is examined in conjunction with both FDA’s regulatory
change in 1973 and mandatory fortiﬁcation in the 1990s
while accounting for a long induction period.Differential Impacts of 1973 Regulatory Change
and 1990's Mandatory Fortiﬁcation by Race
In consequence of the 1973 change, the major group of
individuals whose folate status was expected to improve
was supplement users. According to the National Health
and Nutrition Examination Survey I (1971–1975), the
prevalence of supplement use among the adults aged 20–
74 years was 27.5% in men and 37.9% in women, and
whites were the major users.14 Thus, any beneﬁt asso-
ciated with an improved folate status would be more
pronounced among whites. Although the fortiﬁcation
policy in the 1990s led to a population-level increase in
total folate intake by approximately 100 μg/day, with the
largest increase for whites,15 pre-fortiﬁcation daily total
folate intake of adults aged 45 to 64 years was lowest in
blacks (242 μg/day in men and 206 μg/day in women).15
Given considerable evidence that additional folate intake
results in the greatest reduction in CRC risk among
individuals at low folate status at baseline,10,16,17 blacks
had the greatest potential to beneﬁt from the fortiﬁcation.
In summary, variations by race in the improvement of
folate status predict that the impact of respective folic
acid policy on CRC risk would differ by race as well. This
emphasizes the critical need for investigating the tempo-
ral association between folate intake and CRC by race.Changes in CRC Screening Over Time
in the U.S.
Understanding how screening inﬂuences incidence rates
of CRC over time is crucial to teasing out the effect of
screening from that of folate intake. A landmark trial18
that evaluated the effect of sigmoidoscopy showed that
approximately for the ﬁrst 3 years since the baseline
randomization, incidence rates were higher in the screen-
ing group than in the usual care group because of an
increased detection of asymptomatic CRC by screening.
However, after Year 3, incidence rates became and
remained lower in the screening group presumably
because the removal of precancerous adenomas detected
by screening led to the primary prevention of CRC.
This competing reduction of CRC incidence offset and
then outweighed the initial rise due to an increased
detection. Taken together, it can be inferred that the
initial increase in screening rates is immediately followedwww.ajpmonline.org
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Figure 2. Age-speciﬁc incidence rates of CRC for both
genders by race (1975–2009): (A) whites, (B) blacks
Keum and Giovannucci / Am J Prev Med 2014;46(3S1):S65–S72 S67by a momentary increase in incidence rates without a
time lag for the ﬁrst few years. Of note, the initial rise in
incidence rates in the screening group did not translate
into higher death rates. Mortality, as a function of both
incidence and prognosis, can be reduced by decreasing
incidence or improving prognosis. Screening reduces
mortality through both mechanisms: the detection and
removal of precancerous lesions lead to the primary
prevention of CRC and, thus, lowers incidence; an early
detection of asymptomatic CRC improves prognosis.
Hence, the decreasing trends in mortality in spite of a
momentary rise in incidence rates, which we termed as
the screening bump, serve as the characteristic feature that
distinguishes the effect of screening from the effects of
risk factors that elevate both incidence rates and death
rates in most cases.
Procedures
Based on data from the SEER, the overall secular trend of
CRC in the U.S. was plotted. The trend was further
plotted by age, race, and gender.
Figure 1 presents the overall secular trend, which
shows a sudden increase in CRC incidence rates in the
mid-1990s. This is the ﬁgure that raised the concern that
excess folate intake due to the nationwide fortiﬁcation
might promote colorectal carcinogenesis.7,8 However,
Figures 2–4 show substantial heterogeneity in trends by
subgroups of age, race, and gender, which underscores
that interpretation of the temporal relationship deserves
more delicate explanations.0
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Figure 1. Age-standardized incidence rates of CRC for all
ages, all races, and both genders (1975–2009)
Note: Cancer sites include invasive cases only unless otherwise noted.
Rates are per 100,000 and are age-adjusted to the 2000 U.S. Std
population (19 age groups, Census P25–1130). Regression lines are
calculated using the Joinpoint Regression Program Version 3.5, April
2011, National Cancer Institute. Data source: SEER 9 areas (San
Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle,
Utah, and Atlanta).
CRC, colorectal cancer; SEER, Surveillance, Epidemiology, and End Results
Note: Cancer sites include invasive cases only unless otherwise noted.
Rates are per 100,000. Regression lines are calculated using the
Joinpoint Regression Program Version 3.5, April 2011, National Cancer
Institute. Data source: SEER 9 areas (San Francisco, Connecticut,
Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).
CRC, colorectal cancer; SEER, Surveillance, Epidemiology, and End Results
March 2014Secular Trend of CRC in the U.S. in Relation to
Folate Status
A striking observation is that whites aged Z65 years
experienced a sharp reduction in incidence rates in the
mid-1980s whereas blacks agedZ65 years did in the late
2000s (Figure 2). These secular trends evoke a hypothesis
that adequate folate status during the ages of 45–64 years
may confer beneﬁt on CRC risk later in life. As described
previously, as the major beneﬁciaries of the 1973 reform,
a substantial proportion of whites probably moved from
low to adequate folate status since 1973. If adequate folate
status during the ages of 45–64 years truly confers
protection against CRC in later life, the white supplement
users aged 45–64 years in 1973 should develop less
CRC after allowing sufﬁcient time for a long induction
period between adequate folate intake and CRC. Thus, a
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Figure 3. Incidence/death rates of CRC for whites aged
Z65 (1975–2009)
Note: Cancer sites include invasive cases only unless otherwise noted.
Rates are per 100,000. Regression lines are calculated using the
Joinpoint Regression Program Version 3.5, April 2011, National Cancer
Institute. Data source for incidence rates: SEER 9 areas (San Francisco,
Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and
Atlanta). Data source for death rates: U.S. Mortality Files, National
Center for Health Statistics, CDC.
CRC, colorectal cancer; SEER, Surveillance, Epidemiology, and End Results
Keum and Giovannucci / Am J Prev Med 2014;46(3S1):S65–S72S68reduction in incidence rates of CRC would be predicted
among whites agedZ65 years in the mid-1980s, which is
precisely what was observed in national data (Figure 2A).
Likewise, blacks had the greatest potential to beneﬁt from
the fortiﬁcation in the mid-1990s because of their lowest
pre-fortiﬁcation folate status. Thus, if the hypothesis is
true, then when blacks aged 45–64 years during the
fortiﬁcation era became older in years 2005–2010,
beginning roughly a decade after the practical fortiﬁca-
tion onset (1996), they should have a reduced risk of
CRC. Indeed, a sharp reduction in incidence rates in
blacks aged Z65 years was observed over this time
period (Figure 2B).
Although the data described are compatible with a
reduction in CRC for both whites and blacks after a
decade of respective improved folate status, another
important observation is that only whites, particularly
those agedZ65 years, experienced an abrupt reversal of
downward trends in incidence rates with the initiation of
the fortiﬁcation (Figure 2A). Some raised the concern
that mandatory folic acid fortiﬁcation might be the cause
of the increase in incidence rates.7,8 However, this
explanation7,8 is inconsistent with several lines of epi-
demiologic evidence that suggests a reduced CRC risk
associated with folate intake after a long induction period
but does not support a corresponding immediate
increase in risk, even among supplement users.10,11,19,20
First, a pooled analysis of 13 prospective cohort studies
with 7–20 years of follow-up showed that high folateintake was signiﬁcantly associated with a lower risk
of colon cancer (pooled rate ratio [RR] for Z560 vs
o240 μg/day=0.87, 95% CI=0.78, 0.98; ptrend=0.009).19
Further, in a large cohort study conducted after initiation
of the mandatory fortiﬁcation (1999–2007), higher con-
sumption of total folate intake was not associated with an
increased risk of CRC during the ﬁrst few years (1999–
2001), and a signiﬁcant inverse association was observed
during the 2001–2007 interval.20 Second, even in the only
other human evidence (other than the secular trend data)
that supported an enhancement of CRC with folate, daily
supplementation with 1000 μg folic acid (in addition to
regular diet in the fortiﬁcation era) elevated the risk of
advanced lesions only after 3–5 years of follow-up but
not during the ﬁrst 3 years.21 Of note, after the 1996
fortiﬁcation, the percentage of individuals with total
folate intake over 1000 μg/day remained less than 5%.15
Third, according to a dose–response meta-analysis
including ten nested case–control studies, there was no
evidence of an increased risk of CRC up to circulating
folate level of 73 nmol/L (summary RR for each 10 nmol/L
of circulating folate¼0.96, 95% CI¼0.91, 1.02;
pheterogeneity¼0.58).22 Following folic acid fortiﬁcation in
the U.S., the mean circulating folate level increased from
19.5 nmol/L to 37.2 nmol/L in non-users of B vitamins
and from 30.8 to 40.6 in users of B vitamin supple-
ments.23 Finally, if the temporary increase in CRC
incidence rates had been truly caused by excess folate
intake resulting from the fortiﬁcation, one would expect a
similar increase among whites soon after FDA’s regu-
latory change in 1973. However, Figure 2A suggests no
such indication.
Although these data10,11,19,20 are reassuring against
an increase of CRC following folic acid fortiﬁcation or
supplementation in the general population, it has been
argued that there could be subgroups at high risk,
particularly those with advanced adenomas or early-
stage cancers.24,25 However, in any folic acid interven-
tion trials, most of the cancers diagnosed in the ﬁrst
years were likely to originate from covert advanced
adenomas or latent cancers. Because of randomization,
the proportion of individuals with such neoplasms
should have been equal in the intervention and placebo
groups at baseline. Thus, if folic acid supplementation
promotes the growth of pre-existing neoplasms, an
increased risk of CRC should have been observed in
trials. However, in a recent meta-analysis of 13
randomized, placebo-controlled trials, folic acid sup-
plementation at doses (500–40,000 μg/day) consider-
ably higher than those from fortiﬁcation did not
substantially increase the risk of CRC during the
ﬁrst 5 years of intervention (pooled RR=1.07, 95%
CI=0.83, 1.37; p=0.49).26 Albeit underpowered towww.ajpmonline.org
050
100
150
200
250
300
350
400
450
500
19
75
19
77
19
79
19
81
19
83
19
85
19
87
19
89
19
91
19
93
19
95
19
97
19
99
20
01
20
03
20
05
20
07
20
09
Year of diagnosis/death
R
at
e 
pe
r 1
00
,0
00
0
50
100
150
200
250
300
350
19
75
19
77
19
79
19
81
19
83
19
85
19
87
19
89
19
91
19
93
19
95
19
97
19
99
20
01
20
03
20
05
20
07
20
09
Year of diagnosis/death
R
at
e 
pe
r 1
00
,0
00
0
50
100
150
200
250
300
350
400
450
19
75
19
77
19
79
19
81
19
83
19
85
19
87
19
89
19
91
19
93
19
95
19
97
19
99
20
01
20
03
20
05
20
07
20
09
Year of diagnosis/death
R
at
e 
pe
r 1
00
,0
00
0
50
100
150
200
250
300
350
19
75
19
77
19
79
19
81
19
83
19
85
19
87
19
89
19
91
19
93
19
95
19
97
19
99
20
01
20
03
20
05
20
07
20
09
Year of diagnosis/death
R
at
e 
pe
r 1
00
,0
00
Incidence rate for ages (years):      20–49        50–64 ≥65
Death rate for ages (years): ≥65 
A. White men B. White women 
C. Black men D. Black women 
Figure 4. Age-speciﬁc incidence/death rates of CRC by race and gender (1975–2009): (A) white men; (B) white women; (C)
black men; (D) black women
Note: Cancer sites include invasive cases only unless otherwise noted. Rates are per 100,000. Regression lines are calculated using the Joinpoint
Regression Program Version 3.5, April 2011, National Cancer Institute. Data source for incidence rates: SEER 9 areas (San Francisco, Connecticut,
Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Data source for death rates: U.S. Mortality Files, National Center for Health Statistics, CDC.
CRC, colorectal cancer; SEER, Surveillance, Epidemiology, and End Results
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analysis including three trials whose participants had
a prior history of adenomas and thus a higher risk for
CRC, no evidence for an increased risk of CRC
associated with folic acid supplementation was appa-
rent (RR¼0.76, 95% CI¼0.32, 1.80; p¼0.53).26
Although a potential role of excess folate in progressing
pre-existing subclinical neoplasms could not be com-
pletely dismissed, it is further weakened by the plausi-
bility of an alternative hypothesis that folate might have
a diminished or minimal protective effect on already
established legions.20,27 For instance, in a large cohort
study, a signiﬁcant protective association between total
folate intake and CRC risk became more pronouncedMarch 2014when the analysis was limited to those with history of
endoscopy and, thus, less likely to harbor advanced
adenomas or early-stage cancers.20
Secular Trend of CRC in the U.S. in Relation to
CRC Screening Practices
Although the arguments summarized indicate that folic
acid fortiﬁcation did not account for the bump in CRC
incidence rates among whites agedZ65 years in the later
1990s, it is important to consider alternative explana-
tions. Several observations are consistent with attributing
the sudden increase in incidence rates to a screening
effect. First, the observed pattern of a temporary increase
in incidence rates followed by a return back to the
Keum and Giovannucci / Am J Prev Med 2014;46(3S1):S65–S72S70downward trends while death rates kept decreasing
(Figure 3) resembles the distinctive characteristic of the
screening bump, explained previously. Furthermore, the
speciﬁcity of the bump among whites, with a more
pronounced effect among white men aged Z65 years,
strengthens the evidence for the screening effect
(Figure 4). Considering that meaningful facilitators to
CRC screening include white race and male gender28 and
that age is an independent risk factor for CRC,5 if the
momentary increase in incidence rates had been truly
due to the screening effect, the bump would have been
most evident among elderly white men, which is con-
sistent with national data (Figure 4A). Of note, effective
since January 1, 1998, was the expansion of Medicare
coverage to include fecal occult blood testing (FOBT),
sigmoidoscopy, and colonoscopy for “screening” pur-
poses among high-risk individuals.29 Given that health
insurance coverage is an important facilitator for CRC
screening28 and that the beneﬁciaries of Medicare are
disproportionally whites and elderly over 65 years, the
change in Medicare policy should have most strongly
affected older whites, which is observed in Figure 4 where
only whites agedZ65 years showed the screening bump
in the late 1990s.
In light of the previous explanation that the screening
bump occurs immediately on the initial increase in
screening rates, one might argue that mismatch in time
between the beginning of the observed bump in 1995
and the change in Medicare policy in 1998 counters the
screening effect. However, some evidence supports that
the start of increasing screening rates dates back to 1995.
Fenton et al.29 examined the annual trends of FOBT,
sigmoidoscopy, and colonoscopy from 1995 to 2003
among annual 5% random samples of the Medicare
beneﬁciaries residing in the SEER areas, from which the
data for the secular trends of CRC are generated. The
study showed that since 1995, colonoscopy started to
replace sigmoidoscopy, especially among whites, and
that each year the cumulative increase in colonoscopy
was greater than the cumulative decrease in sigmoido-
scopy, resulting in a net annual increase in rates of
endoscopic tests for CRC starting from 1995. This is also
consistent with the data from the Health Professionals
Follow-up Study, in which majority of the study
population is white and the rates of colonoscopy for
screening purposes started to increase from 1995 (ELG,
unpublished observations, 2013). Thus, both the rising
rates in screening colonoscopy and the temporary increase
in CRC incidence rates beginning in 1995 supports the
screening effect.
Although available data may not be precise enough to
designate deﬁnitively when the rise in colonoscopy usage
in the mid-1990s would have been reﬂected in nationalincidence rates of CRC, a screening bump should have
been evident at some point over this time period given
the substantial increase in endoscopic screening. Because
the observed bump in the late 1990s is the only notable
increase in incidence, it is likely due to the screening
effect. Subsequently, as explained previously, a reduction
in CRC is expected to follow the bump as the removal of
precancerous adenomas detected by screening leads to
the primary prevention of CRC, which is precisely what
was observed in national data (Figure 2A). Thus, for
whites aged Z65 years, although improved folate status
by FDA’s regulatory change in 1973 may have contrib-
uted to the decrease in CRC incidence rates between mid-
1980s and mid-1990s, it is the expansion of screening
endoscopy that is likely to explain a large proportion of
the decrease since the 2000s.Conclusion and Future Directions
Examination of the secular trend of a disease within one
country provides an opportunity to investigate the effects
of nongenetic factors on the disease. Because of inherent
methodologic limitations such as use of group-level data
rather than individual-level information, lack of con-
founding control, and failure to account for the inﬂuence
of changing prevalence of other risk factors over time,
this type of analysis precludes causal inference. None-
theless, by integrating the current state of knowledge on
subject matters, examination of the temporal association
between a nongenetic factor and a disease can engender a
meaningful hypothesis that could suggest a direction for
future research. In this investigation on the U.S. secular
trend of CRC in relation to changing folate status, we
simultaneously accounted for a long time lag between
change in folate status and change in CRC incidence
rates, two major changes in FDA’s regulations that
affected nationwide folate intake, differential impacts of
these policy changes by race, and screening trends. This
approach helped to generate a hypothesis that adequate
folate status during the ages of 45–64 years may confer
beneﬁt on CRC risk in later life, and to alleviate the
enduring concern that the momentary, abrupt increase in
CRC incidence rates in the mid-1990s might have
resulted from excessive folate intake caused by folic acid
fortiﬁcation.
Surely, the proposed hypothesis is not conclusive
because of the aforementioned methodologic limitations.
However, in the U.S., despite the fact that the prevalence
of major CRC risk factors such as the Western dietary
pattern and obesity has been undoubtedly increasing, the
overall incidence rates of CRC have continued to decline.
Although protective agents such as calcium, aspirin,
hormone replacement therapy, and screening endoscopywww.ajpmonline.org
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tributed to the downward trend of CRC incidence rates,
the high prevalence of supplement users and mandatory
folic acid fortiﬁcation provides a unique environment to
the U.S. Thus, folate is more likely to explain the
distinctiveness of the U.S. being the only country in the
world where CRC incidence rates are decreasing. At
present, long-term cohort studies and their pooled
analysis provide compelling evidence for the beneﬁt of
adequate folate intake on CRC.10,11,19 However, results
from RCTs are conﬂicting, and meta-analyses of trials
found no signiﬁcant effect of folic acid supplementation
on CRC.22,26 In general, when assessing the current state
of evidence for the causal relationship between an
exposure and an outcome, more weight is given to results
from RCTs because of their methodologic strengths.
However, assuming a long induction period for folate
to exert its full effect on CRC risk, most of the existing
trials22,26 are limited by their short duration of follow-up
as to provide a deﬁnite conclusion.
It is entirely possible that an important beneﬁt of folic
acid supplementation on CRC could manifest on an
extended follow-up that is sufﬁcient enough to allow for
the long induction period. Furthermore, because trial
participants are mostly health conscious and well nour-
ished and may already have had adequate folate status,
trials targeting individuals with suboptimal folate status
might show a signiﬁcant beneﬁt of folate intake on CRC
risk. Indeed, in a recent RCT among Chinese subjects
with a relatively low baseline folate status, 1000 μg/day
supplementation of folic acid signiﬁcantly reduced the
risk of incident adenoma (RR=0.49, 95% CI=0.37, 0.63;
po0.01).30 Finally, most participants in the existing
trials22,26 were elderly (mean baseline age 460 years)
and, thus, they were not able to address the question of
whether adequate folate intake during the ages of 45–64
years confers a beneﬁt on CRC later in life.
In conclusion, a number of observations suggest that
the increase in CRC incidence rates in the later 1990s in
the U.S. is unlikely to be due to folic acid fortiﬁcation. In
contrast, when assuming a time lag of a decade or longer
to see a beneﬁt on CRC, as suggested by some studies,10,11
folate appears to be one of the most promising factors
that could contribute to the unique downward trend of
CRC incidence rates in the U.S. More studies are needed
to provide deﬁnitive evidence to address the potential
beneﬁts and risks of folate on CRC incidence rates and
mortality. In particular, identiﬁcation of the dose–
response relationship between total folate intake and
CRC risk across a wide range of folate intake over a
sufﬁcient follow-up during the fortiﬁcation era would
help answer whether there is a range of folate intake that
could optimally protect against CRC. A pooled study ofMarch 2014individuals with history of adenomas recruited from
long-established cohorts is warranted to address con-
troversy surrounding a potential role of excess folate in
promoting pre-existing neoplasms with adequate statis-
tical power. Meanwhile, given that the prevalence of
folate deﬁciency is o1% during post-fortiﬁcation in the
U.S.,31 it would be most reasonable that individuals aged
45–64 years, except for those at risk for inadequate folate
status (alcohol abusers, nutrient malabsorbers) target
other risk factors2 and follow recommended screening
schedule for the prevention of CRC. Other countries,
especially those with a low folate status, may consider
implementing nationwide folic acid fortiﬁcation to har-
ness diverse health beneﬁts of achieving adequate folate
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